Skip to content

Advertisement

Journal of Neuroinflammation

Research
Open Access

Inflammation modulates expression of laminin in the central nervous system following ischemic injury

Journal of Neuroinflammation20129:159

https://doi.org/10.1186/1742-2094-9-159

©  Ji and Tsirka; licensee BioMed Central Ltd. 2012

Received: 11 April 2012

Accepted: 3 July 2012

Published: 3 July 2012

Abstract

Background

Ischemic stroke induces neuronal death in the core of the infarct within a few hours and the secondary damage in the surrounding regions over a long period of time. Reduction of inflammation using pharmacological reagents has become a target of research for the treatment of stroke. Cyclooxygenase 2 (COX-2), a marker of inflammation, is induced during stroke and enhances inflammatory reactions through the release of enzymatic products, such as prostaglandin (PG) E2.

Methods

Wild-type (WT) and COX-2 knockout (COX-2KO) mice were subjected to middle cerebral artery occlusion (MCAO). Additionally, brain slices derived from these mice or brain microvascular endothelial cells (BMECs) were exposed to oxygen-glucose deprivation (OGD) conditions. The expression levels of extracellular matrix (ECM) proteins were assessed and correlated with the state of inflammation.

Results

We found that components of the ECM, and specifically laminin, are transiently highly upregulated on endothelial cells after MCAO or OGD. This upregulation is not observed in COX-2KO mice or WT mice treated with COX-2 inhibitor, celecoxib, suggesting that COX-2 is associated with changes in the levels of laminins.

Conclusions

Taken together, we report that transient ECM remodeling takes place early after stroke and suggest that this increase in ECM protein expression may constitute an effort to revascularize and oxygenate the tissue.

Keywords

Extracellular matrix proteinsInflammationIschemiaLaminin

Background

Cerebral ischemia results in neurological disability and constitutes the third leading cause of death in the US. It has devastating consequences as it results in death of neurons at the infarct core within a few hours after the blockade of blood flow to the brain [1]. Although re-establishment of blood flow using fibrinolytics is critical, inflammation that develops following the initial ischemic episode is a major mechanism by which cells in the penumbra degenerate [2], and therefore pharmacological strategies are formulated to limit this delayed phase of damage. Major mediators of inflammatory events are the members of the cyclooxygenase (COX) family. The two major COX isoforms are COX-1 and COX-2 and they catalyze the first step in the transformation of arachidonic acid to prostaglandins (PGs) and thromboxanes. In the central nervous system (CNS), COX-1 and COX-2 are expressed constitutively on neurons, whereas COX-2 is induced on microglia and astrocytes by inflammatory stimuli or injury [3, 4]. COX-2 is considered a proinflammatory mediator leading to PG synthesis [5]. Prostaglandin E2 (PGE2) induces fever and pain, increases vascular permeability and recruit inflammatory cells to injury sites [6]. However, evidence suggests that COX-2 is also involved in inflammation reduction/resolution [7, 8]. The COX-2 inhibitors NS398 and indomethacin have differential effects depending on their administration time: early administration during a pleurisy model suppressed inflammation, but late administration exacerbated inflammation through PGE2 and 15-deoxy-δ12,14-prostaglandin J2 (15d-PGJ2) [7]. In a different paradigm, PGE2 reduced proinflammatory mediators release from mast cells and inflammatory cells recruitment in lungs [9], suppressed inducible nitric oxide synthase (iNOS) and tumor necrosis factor (TNF)α, but enhanced interleukin 10 and interleukin 13 expression in LPS-stimulated microglia [10, 11]. COX-2 also oxygenates anti-inflammatory endocannaboids [12] that protect against ischemic death [13]. These studies suggest that COX-2 can drive or resolve inflammation; therefore, careful regulation of COX-2 may be important for reducing inflammation-mediated neurodegeneration [14, 15].

The extracellular matrix (ECM) of the CNS is essential for maintenance of brain homeostasis. Although its exact composition is not defined, it is thought that hyaluronan, tenascin-C, and proteoglycans are present in brain parenchyma [16], and fibronectin (FN) and laminin in the brain vasculature [17, 18]. Proteoglycans such as aggrecan, versican, and brevican constitute perineuronal nets majorly [19, 20], and tenascin is involved in regulation or promotion of neurite outgrowth [21–23]. Moreover, the structure of these molecules is changed in response to brain injury such as stroke [24, 25]. The ECM and secreted neurotrophic or other factors, such as vascular endothelial growth factor (VEGF) or brain-derived neurotropic factor (BDNF), are involved in neuronal reorganization and recovery in MCAO brains [24, 26–31]. Among the ECM proteins, laminin is rich primarily in the basement membranes of the endothelial cells of the blood–brain barrier (BBB) [32]. Laminin levels have been reported to increase or decrease during CNS injury [29, 33]. Laminins are present in 16 isoforms that are composed of α, β and γ polypeptides. Different laminin isoforms have unique distribution, and are temporally and spatially regulated [34]. Several of the laminin subunits have been shown to be expressed in the rodent brain, including α1 to 5, β1, and γ1 [35, 36], and the β3 and γ1 chains have been reported in sprouting neurons and rat astrocytes [37, 38]. Laminin α2 is localized in the basal lamina of cerebral blood vessels, and may be important for the selective filtration capability of BBB [39]. The expression of laminin is upregulated in endothelial cells and astrocytes within 24 h following ischemia and stab wounds [40, 41].

The work described here investigated whether COX-2 can modulate ECM changes induced by ischemic injury. We focused on laminin as one abundant component of the ECM. Our results indicate that laminin levels on blood vessels are regulated by COX-2 following permanent or transient ischemia. Understanding the functional outcome and timing of laminin expression regulation by COX-2 in the progression of ischemia-induced neuronal damage could suggest a basis for potentially rationalizing drug specific interference with ischemia.

Methods

Animals and in vivo experiments

All animal procedures were approved by the Stony Brook University Institutional Animal Care and Use Committee (IACUC). Adult wild-type (C57BL6; WT) mice were obtained from Jackson Laboratory (Bar Harbor, ME, USA). Cyclooxygenase knockout mice (COX-2KO in the C57Bl6 background) were provided by Dr SK Dey (Cincinnati Children's Hospital). Mice were bred in house at Stony Brook. For middle cerebral artery occlusion (MCAO), mice were anesthetized and underwent permanent MCAO (pMCAO) using a heat-blunted, small 6–0 siliconized monofilament (Ethicon, Somerville, NJ, USA). A fiberoptic probe was glued to the parietal bone (2 mm posterior and 5 mm lateral to bregma) and connected to a laser-Doppler flowmeter (Periflux System 5010, Perimed, Stockholm, Sweden) for continuous monitoring of cerebral blood flow in the ischemic territory center. Celecoxib (Biovision, Milpitas, CA, USA) was given at 5 mg/kg intraperitoneally (in 50 % dimethylsulfoxide (DMSO)) 30 minutes before the injury. The animals were killed at different times. The infarct area was visualized by cresyl violet and 2,3,5-triphenyltetrazolium chloride (TTC) staining.

Tissue preparation

Mice were anesthetized after surgery and perfused with saline solution, followed by 4 % paraformaldehyde (PFA) in 0.1 M phosphate buffer, pH 7.2, for tissue fixation. Brains were obtained and post fixed overnight at 4 °C in 4 % PFA. Fixed brains were stored at 4 °C in 30 % sucrose solution until they sank. Six separate series of 20 μm coronal brain sections were obtained with a cryostat. For protein preparation, mice were anesthetized and perfused with saline. Brains were sliced with Mice Brain Slicer Matrix (ASI Instruments, Warren, MI, USA) and a razor blade. The slice including the ipsilateral sides (ischemic lesion) was selected, and tissue blocks (1.0 × 1.0 × 1.0 mm3) in the lesion of ipsilateral sides and in the same area of contralateral (not ischemic) sides were collected, and stored at −70 °C until use.

Measurement of Infarct volume

To quantify the infarct volume TTC staining was used: mice were killed and perfused with saline after MCAO. The brain slices, obtained as described above, (2 mm) were incubated for 15 minutes in 2 % TTC (Sigma-Aldrich, St. Louis, MO, USA) at 37 °C, and fixed in 4 % PFA at 4 °C. TTC stains viable brain tissue dark red, whereas infarcted tissue areas remain unstained (white). To measure the TTC-negative area, serial sections from each animal were viewed in a Nikon E600 microscope, photographed and the area measured using NIS-Elements software (ImageJ). The infarct volume was calculated as sum of (area × section thickness) for each animal.

Oxygen-glucose deprivation (OGD)

Immortalized human brain microvascular endothelial cells (BMECs) were a gift from Dr M Stins at Johns Hopkins University, School of Medicine [42]. BMECs were cultured in RPMI1640 medium, supplemented with 10 % NuSerum, 10 % fetal bovine serum (FBS), minimal essential medium (MEM) vitamins, MEM non-essential amino acids, 1 mM sodium pyruvate, 2 mM d-glutamine, 30 μg/ml endothelial growth supplement, 5 U/ml heparin, and penicillin/streptomycin at 37 °C in 5 % CO2. The cells form a monolayer connected via tight junctions that can form and model an in vitro blood–brain barrier [43]. For in vitro ischemia, the cells were maintained in glucose-free and serum-free (OGD conditioned) medium under 1 % O2/5 % CO2 at 37 °C (Oxycycler C4, Biospherix, Redfield, NY, USA) for 3 days. Afterwards, the cells were removed from the hypoxic chamber and replaced with pre-OGD conditioned medium in a humidified aerobic incubator at 37 °C for 4 h recovery [44].

Immunoblotting, immunohistochemistry, and immunofluorescence

For immunoblotting, cells or tissue from the ipsilateral or contralateral hemisphere were lysed in 50 mM Tris–HCl (pH 7.4) containing 1 % Nonidet P-40, 0.25 % Na-deoxycholate, 150 mM NaCl, and protease inhibitors cocktail (Sigma-Aldrich) using a homogenizer on ice, incubated for 30 minutes, and centrifuged. The extracts were run on a reducing 10 % sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene fluoride (PVDF) membrane (Immobilon-P; Millipore, Billerica, MA, USA). The blots were incubated using primary antibodies (Table 1) overnight at 4 °C; followed by incubation with horseradish peroxidase-labeled secondary antibody (Invitrogen, Carlsbad, CA, USA) for 1 h at room temperature, and enhanced chemiluminescence (ECL) (Pierce Chemical Co., Rockford, IL, USA). After stripping, the membranes were reblotted with mouse anti-α-tubulin (Upstate Biotechnology, Lake Placid, NY, USA) antibody. Expression levels were quantified using the ImageJ software, normalized against α-tubulin. For immunohistochemistry and immunofluorescence, sections were fixed in 4 % PFA in phosphate-buffered saline (PBS) for 30 minutes. After washing in PBS, they were blocked in 0.2 % Triton X-100 and 1 % bovine serum albumin (BSA) in PBS. The primary antibodies used were listed in Table 1. The sections were incubated with primary antibody in 0.2 % Triton X-100 and 1 % BSA in PBS at 4 °C overnight. After rinsing in PBS, the sections were incubated with biotinylated secondary antibodies, the avidin/biotin system, and visualized using 3,3'-diaminobenzidine, or Alexa Fluor488-conjugated or Alexa Fluor555-conjugated secondary antibodies (Invitrogen) for 1 h. The sections were rinsed in PBS, coverslipped, and examined using confocal microscopy or epifluorescence microscopy.
Table 1

Antibodies used for immunostaining or immunoblotting

Antigen

Antibody

Dilution

Source

Catalog no.

Method

NeuN

Mouse monoclonal

1:1,000

Chemicon

MAB377

IHC

Iba-1

Rabbit polyclonal

1:1,000

Wako

019-19741

IHC

TLR9

Rabbit polyclonal

1:500

Imgenex

IMG431

WB

CD14

Goat polyclonal

1:1,000

Santa Cruz Biotechnology

sc-6999

WB

Fibrin

Mouse monoclonal

1:200

A gift of Dr Galanakis

[45]

WB

Collagen IV

Rabbit polyclonal

1:500

Chemicon

AB756

WB

Pan-laminin

Rabbit polyclonal

1:1,000

Sigma-Aldrich

L9393

IHC

  

1:5,000

  

WB

α-Tubulin

Mouse monoclonal

1:7,000

Upstate Biotechnology

05-829

WB

Occludin

Mouse monoclonal

1:250

Zymed

33-1500

IHC

HIF-1α

Rabbit polyclonal

1:1,000

Bethyl Laboratories

A300-286A

WB

COX-2

Mouse monoclonal

1:500

BD Biosciences

610203

WB

Mac-2

Rat monoclonal

1:1,000

Cedarlane

CL8942AP

WB

CD45

Rat monoclonal

1:500

BD Biosciences

553076

IHC

VEGF

Rabbit polyclonal

1:200

Thermo scientific

RB-9031

WB

GFAP

Rabbit polyclonal

1:1,000

DAKO

Z0334

IHC

COX-2, cyclooxygenase 2; GFAP, glial fibrillary acidic protein; HIF-1α, hypoxia-inducible factor 1α; Iba-1, ionized calcium binding adaptor molecule 1; IHC, immunohistochemisty; TLR9, Toll-like receptor 9; VEGF, vascular endothelial growth factor; WB, western blot.

Reverse transcription polymerase chain reaction (RT-PCR)

Total RNA was extracted using TRIzol (Invitrogen) and cDNA was prepared using reverse transcriptase, according to manufacturer’s instructions (Invitrogen). The PCR primers used are listed in Table 2. PCR products were separated by electrophoresis in 1 % agarose gels and detected under ultraviolet (UV) light.
Table 2

Primer sequences for reverse transcription polymerase chain reaction (RT-PCR)

Gene

Forward/reverse

Sequences (5’-3’)

Laminin α2

F

GCCGCACTCCTGGACCAACC

 

R

TGCCAGTGCTCGCAGCCATC

Laminin α4

F

ATCGAGGGGAGCGCAGTGGT

 

R

GCAGAACCGGGGTGTGCCTC

Laminin α5

F

CTGTGGAGCCCGCCTGTGTG

 

R

CCCCACGCGACACTGGTCAC

Laminin β1

F

CGAACCTGCAGCGAGTGCCA

 

R

GTTCCGCTGCTGGGCTCTGG

Laminin β3

F

CCAGCGCACACGGCTTCTCA

 

R

GTGCCCTGCCGAAGGTTCCC

Laminin γ1

F

CTGTGAGACTGTGCCGCCCG

 

R

ACAGTGCTGGCCGGTGATGC

Laminin γ2

F

CGGCTGTGTGTAGCGGGGTG

 

R

CAGCAGGAGCGCGACACCAA

actin

F

GCTCGTCGTCGACAACGGCT

 

R

CAAACATGATCTGGGTCATCTTCTC

Using permanent MCAO we followed the effect of ischemia and local inflammation, and using transient MCAO we followed the effect of systemic inflammatory cell infiltration on changes in ECM proteins during post-injury CNS reorganization.

Statistics

Statistical significance was assessed by analysis of variance (ANOVA), followed by Student-Newman-Keuls multiple comparison tests. All analyses were performed using SPSS, V.8.0 (SPSS, Chicago, IL, USA). Values are means ± SEMs of at least three independent experiments using at least five animals per experimental procedure and mouse strain, unless otherwise indicated.

Results

Laminin expression is transiently upregulated in wild-type, but not COX-2KO, mice after MCAO

We used permanent MCAO (pMCAO) to investigate how ischemia-induced local inflammatory events affect the ECM. The extent of neuronal death and local inflammation (microglial cell activation) were assessed over time. The number of Nissl bodies was reduced at 3 h compared to that in contralateral sides following pMCAO (Figure 1A,B and Additional file 1: Figure S1) and the infarct volume was increased (Figure 1E). Regions not stained with TTC indicating cerebral infarction were observed within 6 h following pMCAO (Figure 1C). The state of microglial activation was also visualized using the Iba-1 marker, which is specific for macrophages/microglia (Figure 1D). Change of microglial morphology to an ameboid state was observed using Iba-1 staining within 1 to 3 h after pMCAO, and sustained until at least 48 h after the injury. Similarly, the infiltration of leukocytes was assessed after MCAO (Additional file 1: Figure S1): immunoreactivity for CD45 was evident 1 h after MCAO, as well as at later timepoints, namely at 24 and 48 h.
Figure 1
Figure 1

Neuronal death and Iba + microglia in ischemic brain following middle cerebral artery occlusion (MCAO). Sections at the indicated times after MCAO were stained with cresyl violet (B), 2,3,5-triphenyltetrazolium chloride (TTC) (C), and Iba-1 antibody (D). Contralateral sides were used as controls. Upper and lower sections are from the cortex and striatum, respectively. The sections were stained with cresyl violet; the areas of neuronal death were revealed by the absence of cresyl violet stain and are represented in the cartoons as gray shading (A). (E) Infarct volume was measured as described in the Methods section. Data were obtained from five animals per timepoint. Values are means ± SEMs of at least three independent experiments of each group unless otherwise indicated. Bars, 50 μm.

As COX-2 is one of the critical contributors to microglial activation [4], we assessed the extent of neuronal death and other parameters in COX-2−/− mice (COX-2KO) relative to wild-type (WT) animals. COX-2KO mice were subjected to MCAO alongside WT animals. At 12 h after injury the extent of neurodegeneration in COX-2KO mice was decreased compared to WT mice (Figure 2A, upper and infarct volume graph), as reported previously [46]. Microglial activation was similarly reduced (data not shown). When we evaluated the expression of common ECM components, we found that proteins such as laminin, fibrinogen, fibronectin (not shown), and collagen IV were upregulated in ischemic brain (Figure 2B,C). The markers tested exhibited a transient increase after MCAO in WT animals. This transient increase was not detectable in the sham and contralateral (not ischemic) side, marked in Figure 2B, C as C12 (contralateral side 12 h post MCAO). In COX-2KO tissue extracts, the transient increase was not observed at the time points examined. This result suggests that the MCAO injury probably induces and COX-2 could be involved in an inflammation-mediated change in the ECM protein expression.
Figure 2
Figure 2

Impaired laminin expression in COX-2 knockout (COX-2KO) mice following ischemic injury. Lower magnification images of cresyl violet staining ((A), upper) on brain sections from wild-type (WT control) and COX-2KO, mice that were subjected to middle cerebral artery occlusion (MCAO). Sections shown were collected 12 h after MCAO and stained with cresyl violet. White dotted lines demarcate the infarct. *P <0.05 compared to WT control or WT vehicles. (B,C) Extracellular matrix (ECM) protein expression in extracts from ipsilateral sides after MCAO was analyzed for Toll-like receptor 9 (TLR9), CD14, fibrin(ogen), collagen IV (B), and laminin levels (α, β and γ subunits) (C) and was quantified using the ImageJ software, normalized against α-tubulin and graphed as fold difference in mean intensity. *P <0.01 compared to the contralateral WT and COX-2KO sides at 12 h (C12). Data were obtained from at least five animals in each group.

Since laminin was the ECM protein whose levels were predominantly affected by MCAO, and given the known involvement of laminin in revascularization, we examined whether the MCAO and ECM changes also involved changes in the expression of VEGF, a factor known for mediating angiogenesis and neoangiogenesis. As shown in Additional file 2: Figure S2, the levels of VEGF were elevated in wild-type animals at 6 and 12 h post MCAO (peak at 6 h), but this increase was drastically attenuated in COX-2KO mice, suggesting that COX-2 could be involved in laminin-mediated angiogenesis [47].

Laminin is increased in endothelial cells after ischemic injury

Among the ECM markers investigated, the most prominent change in protein levels was observed in laminin, as shown in Figure 2C. In the subsequent experiments we focused our investigation on laminin and its expression after stroke. To ascertain the cellular localization of laminin, we used occludin as an indicator of endothelial cells on the blood vessels since laminin has been considered as a major component of the ECM of the BBB [17]. Laminin expression was prevalent on occludin+ cells (Figure 3A), demonstrating that endothelial cells were one cellular source of upregulated laminin [36, 48]. To further confirm that laminin expression was increased on endothelial cells, brain microvascular endothelial cells (BMECs) were subjected to conditions of OGD, as described in the Methods section, and analyzed by immunoblotting. Laminin expression, in particular β and γ subunits, was upregulated on endothelial cells following injury (Figure 3B).
Figure 3
Figure 3

Laminin expression increased on blood vessels following transient middle cerebral artery occlusion (tMCAO). (A) At 6 h post MCAO, sections were stained with antibodies against anti-pan-laminin and occludin. Data are representative of results from at least five animals. Scale bar, 100 μm. (B) Brain microvascular endothelial cells (BMECs) were challenged with oxygen-glucose deprivation (OGD) and assayed for laminin expression. *P <0.01 compared to control. (C) RT-PCR for laminin subtypes at indicated times after MCAO.

The antibody used in Figures 2C and 3A,B was a pan-laminin antibody, so we sought to determine which laminin subunits are upregulated after MCAO. We used semiquantitative RT-PCR for each laminin subunit in extracts from the ipsilateral side of MCAO animals at the indicated times (Figure 3C). The analysis showed that laminins α2, β3, and γ1 were upregulated within 24 h (Figure 3C).

Pharmacological inhibitors of COX-2 modulate laminin levels after MCAO

COX-2 deficiency modulated the levels of several ECM markers following MCAO (Figure 2B,C). Focusing again on laminin, we assessed whether this effect of COX-2 was acute or rather a potential developmental effect. To address this concern, we impaired COX-2 activity pharmacologically using celecoxib (coxib). We used first OGD in culture, as described above. Coxib was given at 2.5 and 5 μM during the OGD and the levels of laminin were examined using immunoblotting. As shown in Figure 4A,B, the OGD samples had higher levels of laminin compared to control samples. When coxib was used, the levels of laminin were decreased down to control levels. Similar to laminin, the hypoxia inducible factor 1α (HIF-1α), which a classic marker upregulated during ischemia or OGD [49], was decreased in the presence of coxib. The levels of α-tubulin or COX-2 remained the same in all conditions. Coxib was also administered in vivo to wild-type mice immediately before MCAO. More intact Nissl bodies were observed in coxib-treated mice (WT + coxib) compared to control ones that had not been treated with coxib (WT + vehicle) (Figure 4C). In these Nissl- area, laminin expression was dramatically decreased in coxib-treated mice (+coxib) compared to control mice (vehicle) (Figure 4C,D) and was reminiscent of laminin expression levels in COX-2KO mice. Notably, the intense staining indicating increased expression of blood vessels (endothelial cells) was not observed in the coxib-treated animal tissues. These results suggest that COX-2 can regulate acutely laminin expression.
Figure 4
Figure 4

Impaired laminin expression in cyclooxygenase 2 (COX-2)-inhibited cells and mice following ischemic injury. (A) Brain microvascular endothelial cells (BMECs) were treated with celecoxib (coxib, 2.5 and 5 μM) and subjected to oxygen-glucose deprivation (OGD). (B) Laminin expression was determined in cell extracts. α-Tubulin normalized protein loading. Bands were quantified by densitometry and plotted as mean intensity. The value of laminin expression in bar graph was averaged over all experiments for the expression of all laminin subunits; *P <0.01. (C) Lower magnification images of cresyl violet staining (upper) of brain sections from wild-type (WT) mice treated with vehicle alone (WT + vehicle) and the COX-2 inhibitor coxib (WT + coxib) prior to middle cerebral artery occlusion (MCAO). White dotted lines demarcate the infarct. Infarct volume was measured. *P <0.05 compared to WT vehicle (lower). (D) Sections shown were collected 12 h after MCAO and stained with pan-laminin antibodies. Data are representative of results from three independent experiments. Bars, 50 μm.

COX-2 acts through E-prostanoid 3 (EP3) receptors to modulate ECM protein expression

We assessed whether the effect of COX-2 on laminin and ECM protein expression was mediated through prostaglandins and prostaglandin receptors. We used pharmacological inhibitors of EP receptors on BMECs and subjected them to OGD. Of the antagonists used, SC51089 (EP1), AH6809 (EP2), L798,106 (EP3) and AH23848 (EP4), only the EP3 antagonist decreased laminin levels (Figure 5A). The combination of coxib and L798,106 did not result in further laminin decrease expression (Figure 5B). This result suggests that COX-2 regulates laminin expression via EP3 receptor activation, which mainly function to inhibit adenylyl cyclase via Gi activation [50].
Figure 5
Figure 5

Decreased laminin expression in cyclooxygenase 2 (COX-2)-inhibited endothelial cells following oxygen-glucose deprivation (OGD). (A) Cells were pretreated with antagonists, subjected to OGD and western blot analysis. AH, AH6809 (1 μM; Ki = 350 nM), EP2 antagonist; L, L798,106 (1 nM; Ki = 0.3 nM), EP3 antagonist; A, AH23848 (1 μM; IC50 = 0.26 μM), EP4 antagonist. (B) Laminin expression in COX-2-inhibited endothelial cells following OGD. Cells were pretreated with antagonists, subjected to OGD and western blot analysis. (C) Brain microvascular endothelial cells (BMECs) were pretreated with celecoxib (coxib) and antagonists for 15 minutes, then subjected to OGD and western blot analysis using antibodies against Toll-like receptor 9 (TLR9) and Mac-2. α-Tubulin was used to normalize protein loading. Quantification was performed using the ImageJ software, normalized against α-tubulin. *P <0.01 compared to control. Data are representative of results from at leas five experiments.

As discussed earlier, in Figure 2, other ECM protein components were also increased after MCAO, and their expression correlated with increased inflammation. We evaluated the expression of markers not directly associated with the COX-2 pathway (TLR9, Mac-2, CD14) in the presence of coxib or EP antagonists, and found that their expression was also decreased when the COX-2 pathway was inhibited (Figure 5C). These results suggested that laminin and other ECM protein expression increase is associated with brain inflammation.

Because the EP3 inhibitor inhibited the induction of laminin (Figure 5A), we explored whether incubation of BMECs with PGE2 would result in increase of laminin expression. The cells were treated with increasing concentrations of PGE2 over a period of 2 days. As shown in Figure 6, a strong upregulation of all laminin subunits was evident at the 1-day but mostly at the 2-day timepoint. This result further supports the involvement of COX-2/PGE2 in the processes that lead to laminin induction.
Figure 6
Figure 6

Laminin protein levels increase after treatment of endothelial cells with prostaglandin E 2 (PGE 2 ). BMECs were treated with 0.1 and 1 μM PGE2 for 1 or 2 days. At the end of the incubation period the cells were lysed and subjected to western blot analysis to reveal laminin protein levels. α-Tubulin was used to normalize protein loading. Data are representative of three experiments. The α, β and γ subunits are indicated by arrows. *P <0.01 compared to control.

Discussion

ECM components play regulatory roles in various cellular events [51–53], including healing/repair processes after injury [54]. For some ECM proteins it has been reported that their expression increases in ischemia and stab wounds [40, 41], but it is not known what its contribution to the injury outcome is. Focusing on one ECM component, we report that the increase in laminin depends on COX-2 activity.

Laminin upregulation has been linked to wound healing stimulation [54, 55] and angiogenesis. In a skin wound model, application of laminin peptides increased the wound coverage and repair and was accompanied by enhanced angiogenesis. Laminins α2, β3, and γ1 are increased in brain following transient ischemic injury. These laminins have been reported to be expressed in brain [33, 38, 56]. The biological roles of laminin subtypes and trimer molecules are largely unknown, thus, information about their functions derives from the phenotype of deficient or knockout mice. Laminin α1 is involved in epiblast differentiation [34]. Laminin α2 is expressed in basal lamina surrounding neurons and muscle [57]. α2 deficiency causes congenital muscular dystrophy [58]. Laminin β1 deficient mice lack basement membranes and display defects in the neuromuscular synapse [34]. Laminin β3 is expressed on the basal lamina and ECM of all cerebral microvessels [59]. The γ1 subunit is rapidly degraded during excitotoxicity [60] or ethanol-induced neurodegeneration [61]. Although these subunits were upregulated after MCAO, it is not clear if they form a single laminin isoform or distinct heterotrimers. Moreover, it is not clear if they would act through the same receptors, integrins, dystroglycan or syndecan [34].

COX-2 activity enhances the production of VEGF [47], which in turn stimulates angiogenesis. The downstream effectors of COX-2 would be different prostaglandins such as PGI2, PGD2, PGE2, PGF2α, and thromboxane (Tx). These prostaglandins bind to the receptor with the greatest affinity: I prostanoid (IP) receptor binds PGI2, DP binds PGD2, EP binds PGE2, FP binds PGF2α, and TP binds TxA2, and they are basically G protein-coupled prostanoid receptors (GPCR) [62, 63]. Among the prostaglandins, prostaglandin E2 (PGE2) is the most widely produced prostaglandin in the body, and considered to participate in inflammation associated with redness, swelling and pain [64, 65] and has significant effects on proliferation, the apoptosis of lymphocytes and the regulation of cytokine production in T cells [64]. PGE2 has the most known receptors with EP subtypes characterized as EP1 to EP4. Depending on the model of CNS injury, different EP receptors mediate the cellular signals. In a model of pulmonary emphysema angiogenesis was mediated by an EP2 agonist [66], whereas bone marrow cells expressing EP3 receptor enhanced angiogenesis during chronic inflammatory conditions [67]. In Lewis lung carcinoma the proangiogenic microenvironment was regulated via COX-2/EP3 or EP4 signaling [56]. In our study the effects of COX-2 on laminin expression were mediated through EP3 receptors. Our results suggest that although ECM changes are associated with the general acute inflammatory processes after MCAO, they may result from specific signaling changes. This latter hypothesis is supported by the fact that not all EP antagonists affect laminin expression, yet all affect other marker expression.

The observation that eventually laminin expression was recovered in COX-2-deficient animals at 2 days (data not shown) suggests that COX-2 deficiency delays the upregulation of the ECM protein laminin, potentially due to the release of different prostaglandins at early and late inflammatory stages and/or neuronal recovery during ischemic injury.

If the initial response of the ischemic tissue is an effort to promote neoangiogenesis to re-establish the blood flow [68, 69], our data suggest that the early inflammatory reactions may be aiding such a process. Our results also point to molecular components critical for increased vascularization, suggesting that inhibition of molecules, such as EP3, may not be beneficial for stroke outcome.

Conclusions

Our study shows that following MCAO a transient upregulation of proteins of the ECM is observed, primarily of proteins associated with the endothelial cells of the CNS blood vessels. The presence of COX-2 and the pathway it initiates are important for this upregulation. Although we do not currently know why this ECM protein changes occur, we speculate that they constitute an early endogenous proangiogenic attempt from the tissue to re-establish oxygenation of the surrounding tissue.

Declarations

Acknowledgements

We thank Drs Feng and van Nostrand for helping us with the MCAO models, and Dr Colognato’s lab for advice. This study was supported by AHA-EIA0540107N and R01NS42168 (SET).

Authors’ Affiliations

(1)
Department of Pharmacology, Stony Brook University, Stony Brook, USA

References

  1. Dirnagl U, Iadecola C, Moskowitz M: Pathobiology of ischemic stroke: an integrated view. Trends Neurosci 1999, 22:391–397.View ArticlePubMedGoogle Scholar
  2. Wang Q, Tang X, Yenari M: The inflammatory response in stroke. J Neuroimmunol 2007, 184:53–68.View ArticlePubMedGoogle Scholar
  3. Feng L, Sun W, Xia Y, Tang W, Chanmugam P, Soyoola E, Wilson C, Hwang D: Cloning two isoforms of rat cyclooxygenase: differential regulation of their expression. Arch Biochem Biophys 1993, 307:361–368.View ArticlePubMedGoogle Scholar
  4. Planas A, Soriano M, Rodriguez-Farre E, Ferrer I: Induction of cyclooxygenase-2 mRNA and protein following transient focal ischemia in the rat brain. Neurosci Lett 1995, 200:187–190.View ArticlePubMedGoogle Scholar
  5. Herschman H: Prostaglandin synthase 2. Biochim Biophys Acta 1999, 1299:125–140.View ArticleGoogle Scholar
  6. Kawano Y, Nakamura S, Fukuda J, Miyakawa I: Synergistic effect of interleukin-1alpha and ceramide analogue on production of prostaglandin E2 and F2alpha by endometrial stromal cells. Am J Reprod Immunol 2001, 46:393–398.View ArticlePubMedGoogle Scholar
  7. Gilroy D, Colville-Nash P, Willis D, Chivers J, Paul-Clark M, Willoughby D: Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 1999, 5:698–701.View ArticlePubMedGoogle Scholar
  8. Graham S, Hickey R: Cyclooxygenases in central nervous system diseases: a special role for cyclooxygenase 2 in neuronal cell death. Arch Neurol 2003, 60:628–630.View ArticlePubMedGoogle Scholar
  9. Vancheri C, Mastruzzo C, Sortino M, Crimi N: The lung as a privileged site for the beneficial actions of PGE2. Trends Immunol 2004, 25:40–46.View ArticlePubMedGoogle Scholar
  10. Yang M, Ji K, Jeon S, Jin B, Kim S, Jou I, Joe E: Interleukin-13 enhances cyclooxygenase-2 expression in activated rat brain microglia: implications for death of activated microglia. J Immunol 2006, 177:1323–1329.View ArticlePubMedGoogle Scholar
  11. Harizi H, Juzan M, Pitard V, Moreau J, Gualde N: Cyclooxygenase-2-issued prostaglandin e(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions. J Immunol 2002, 168:2255–2263.View ArticlePubMedGoogle Scholar
  12. Eljaschewitsch E, Witting A, Mawrin C, Lee T, Schmidt P, Wolf S, Hoertnagl H, Raine C, Schneider-Stock R, Nitsch R, Ullrich O: The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 2006, 49:67–79.View ArticlePubMedGoogle Scholar
  13. Nagayama M, Niwa K, Nagayama T, Ross M, Iadecola C: The cyclooxygenase-2 inhibitor NS-398 ameliorates ischemic brain injury in wild-type mice but not in mice with deletion of the inducible nitric oxide synthase gene. J Cereb Blood Flow Metab 1999, 19:1213–1219.View ArticlePubMedGoogle Scholar
  14. Kawano T, Anrather J, Zhou P, Park L, Wang G, Frys K, Kunz A, Cho S, Orio M, Iadecola C: Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat Med 2006, 12:225–229.View ArticlePubMedGoogle Scholar
  15. Liang X, Wu L, Wang Q, Hand T, Bilak M, McCullough L, Andreasson K: Function of COX-2 and prostaglandins in neurological disease. J Mol Neurosci 2007, 33:.Google Scholar
  16. Rauch U: Extracellular matrix components associated with remodeling processes in brain. Cell Mol Life Sci 2004, 61:2031–2045.View ArticlePubMedGoogle Scholar
  17. Bellail A, Hunter S, Brat D, Tan C, Van Meir E: Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell Biol 2004, 36:1046–1069.View ArticlePubMedGoogle Scholar
  18. Jones J, Lane K, Hopkinson S, Lecuona E, Geiger R, Dean D, Correa-Meyer E, Gonzales M, Campbell K, Sznajder J, Budinger S: Laminin-6 assembles into multimolecular fibrillar complexes with perlecan and participates in mechanical-signal transduction via a dystroglycan-dependent, integrin-independent mechanism. J Cell Sci 2005, 118:2557–2566.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Yamaguchi Y: Lecticans: organizers of the brain extracellular matrix. Cell Mol Life Sci 2000, 57:276–289.View ArticlePubMedGoogle Scholar
  20. Giamanco K, Morawski M, Matthews R: Perineuronal net formation and structure in aggrecan knockout mice. Neuroscience 2010, 170:1314–1327.View ArticlePubMedGoogle Scholar
  21. Yu Y, Cristofanilli M, Valiveti A, Ma L, Yoo M, Morellini F, Schachner M: The extracellular matrix glycoprotein tenascin-C promotes locomotor recovery after spinal cord injury in adult zebrafish. Neuroscience 2011, 183:238–250.View ArticlePubMedGoogle Scholar
  22. Zacharias U, Rauch U: Competition and cooperation between tenascin-R, lecticans and contactin 1 regulate neurite growth and morphology. J Cell Sci 2006, 119:3456–3466.View ArticlePubMedGoogle Scholar
  23. Rigato F, Garwood J, Calco V, Heck N, Faivre-Sarrailh C, Faissner A: Tenascin-C promotes neurite outgrowth of embryonic hippocampal neurons through the alternatively spliced fibronectin type III BD domains via activation of the cell adhesion molecule F3/contactin. J Neurosci 2002, 22:6596–6609.PubMedGoogle Scholar
  24. Fukuda S, Fini C, Mabuchi T, Koziol J, Eggleston LJ, del Zoppo G: Focal cerebral ischemia induces active proteases that degrade microvascular matrix. Stroke 2004, 35:998–1004.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Baeten K, Akassoglou K: Extracellular matrix and matrix receptors in blood–brain barrier formation and stroke. Dev Neurobiol 2011, 71:1018–1039.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Nagel S, Sandy J, Meyding-Lamade U, Schwark C, Bartsch J, Wagner S: Focal cerebral ischemia induces changes in both MMP-13 and aggrecan around individual neurons. Brain Res 2005, 1056:43–50.View ArticlePubMedGoogle Scholar
  27. Hobohm C, Günther A, Grosche J, Rossner S, Schneider D, Brückner G: Decomposition and long-lasting downregulation of extracellular matrix in perineuronal nets induced by focal cerebral ischemia in rats. J Neurosci Res 2005, 80:539–548.View ArticlePubMedGoogle Scholar
  28. Smirkin A, Matsumoto H, Takahashi H, Inoue A, Tagawa M, Ohue S, Watanabe H, Yano H, Kumon Y, Ohnishi T, Tanaka J: Iba1(+)/NG2(+) macrophage-like cells expressing a variety of neuroprotective factors ameliorate ischemic damage of the brain. J Cereb Blood Flow Metab 2010, 30:603–615.View ArticlePubMedGoogle Scholar
  29. Han Q, Li B, Feng H, Xiao Z, Chen B, Zhao Y, Huang J, Dai J: The promotion of cerebral ischemia recovery in rats by laminin-binding BDNF. Biomaterials 2011, 32:5077–5085.View ArticlePubMedGoogle Scholar
  30. Ellison J, Velier J, Spera P, Jonak Z, Wang X, Barone F, Feuerstein G: Osteopontin and its integrin receptor alpha(v)beta3 are upregulated during formation of the glial scar after focal stroke. Stroke 1998, 29:1698–1706.View ArticlePubMedGoogle Scholar
  31. Meller R, Stevens S, Minami M, Cameron J, King S, Rosenzweig H, Doyle K, Lessov N, Simon R, Stenzel-Poore M: Neuroprotection by osteopontin in stroke. J Cereb Blood Flow Metab 2005, 25:217–225.View ArticlePubMedGoogle Scholar
  32. Engel J, Furthmayr H: Electron microscopy and other physical methods for the characterization of extracellular matrix components: laminin, fibronectin, collagen IV, collagen VI, and proteoglycans. Methods Enzymol 1987, 145:3–78.View ArticlePubMedGoogle Scholar
  33. Indyk J, Chen Z, Tsirka S, Strickland S: Laminin chain expression suggests that laminin-10 is a major isoform in the mouse hippocampus and is degraded by the tissue plasminogen activator/plasmin protease cascade during excitotoxic injury. Neuroscience 2003, 116:359–371.View ArticlePubMedGoogle Scholar
  34. Durbeej M: Laminins. Cell Tissue Res. 2010, 339:259–268.View ArticlePubMedGoogle Scholar
  35. Sixt M, Engelhardt B, Pausch F, Hallmann R, Wendler O, Sorokin L: Endothelial cell laminin isoforms, laminins 8 and 10, play decisive roles in T cell recruitment across the blood–brain barrier in experimental autoimmune encephalomyelitis. J Cell Biol 2001, 153:933–946.View ArticlePubMedPubMed CentralGoogle Scholar
  36. Hagg T, Portera-Cailliau C, Jucker M, Engvall E: Laminins of the adult mammalian CNS; laminin-alpha2 (merosin M-) chain immunoreactivity is associated with neuronal processes. Brain Res 1997, 764:17–27.View ArticlePubMedGoogle Scholar
  37. Li S, Overman J, Katsman D, Kozlov S, Donnelly C, Twiss J, Giger R, Coppola G, Geschwind D, Carmichael S: An age-related sprouting transcriptome provides molecular control of axonal sprouting after stroke. Nat Neurosci 2010, 13:1496–1504.View ArticlePubMedPubMed CentralGoogle Scholar
  38. Wagner S, Gardner H: Modes of regulation of laminin-5 production by rat astrocytes. Neurosci Lett 2000, 284:105–108.View ArticlePubMedGoogle Scholar
  39. Villanova M, Malandrini A, Sabatelli P, Sewry CA, Toti P, Torelli S, Six J, Scarfó G, Palma L, Muntoni F, Squarzoni S, Tosi P, Maraldi NM, Guazzi GC: Localization of laminin alpha 2 chain in normal human central nervous system: an immunofluorescence and ultrastructural study. Acta Neuropathol 1997, 94:567–571.View ArticlePubMedGoogle Scholar
  40. Jucker M, Bialobok P, Kleinman H, Walker L, Hagg T, Ingram D: Laminin-like and laminin-binding protein-like immunoreactive astrocytes in rat hippocampus after transient ischemia. Antibody to laminin-binding protein is a sensitive marker of neural injury and degeneration. Ann NY Acad Sci 1993, 679:245–252.View ArticlePubMedGoogle Scholar
  41. Szabo A, Kalman M: Disappearance of the post-lesional laminin immunopositivity of brain vessels is parallel with the formation of gliovascular junctions and common basal lamina. A double-labelling immunohistochemical study. Neuropathol Appl Neurobiol 2004, 30:169–177.View ArticlePubMedGoogle Scholar
  42. Callahan M, Williams K, Kivisakk P, Pearce D, Stins M, Ransohoff R: CXCR3 marks CD4+ memory T lymphocytes that are competent to migrate across a human brain microvascular endothelial cell layer. J Neuroimmunol 2004, 153:150–157.View ArticlePubMedGoogle Scholar
  43. Yao Y, Tsirka S: Truncation of monocyte chemoattractant protein 1 by plasmin promotes blood–brain barrier disruption. J Cell Sci 2011, 124:1486–1495.View ArticlePubMedPubMed CentralGoogle Scholar
  44. Seidel S, Garvalov BK, Wirta V, von Stechow L, Schänzer A, Meletis K, Wolter M, Sommerlad D, Henze AT, Nistér M, Reifenberger G, Lundeberg J, Frisén J, Acker T: A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain 2010, 133:983–995.View ArticlePubMedGoogle Scholar
  45. Galanakis DK, Henschen-Edman A, Weisel J, Spitzer S: Antifibrinogen IgG, fibrinogen, and Clq complexes circulating in a hypodysfibrinogenemic proband. Isolation, stoichiometry, and partial characterization. Ann N Y Acad Sci 2001, 936:611–616.View ArticlePubMedGoogle Scholar
  46. Iadecola C, Niwa K, Nogawa S, Zhao X, Nagayama M, Araki E, Morham S, Ross M: Reduced susceptibility to ischemic brain injury and N-methyl-d-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci USA 2001, 98:1294–1299.View ArticlePubMedPubMed CentralGoogle Scholar
  47. Yanni S, McCollum G, Penn J: Genetic deletion of COX-2 diminishes VEGF production in mouse retinal Müller cells. Exp Eye Res 2010, 91:34–41.View ArticlePubMedPubMed CentralGoogle Scholar
  48. Hagg T, Muir D, Engvall E, Varon S, Manthorpe M: Laminin-like antigen in rat CNS neurons: distribution and changes upon brain injury and nerve growth factor treatment. Neuron 1989, 3:721–732.View ArticlePubMedGoogle Scholar
  49. Filiano A, Bailey C, Tucholski J, Gundemir S, Johnson G: Transglutaminase 2 protects against ischemic insult, interacts with HIF1beta, and attenuates HIF1 signaling. FASEB J 2008, 22:2662–2675.View ArticlePubMedPubMed CentralGoogle Scholar
  50. Ikeda-Matsuo Y, Tanji H, Ota A, Hirayama Y, Uematsu S, Akira S, Sasaki Y: Microsomal prostaglandin E synthase-1 contributes to ischaemic excitotoxicity through prostaglandin E2 EP3 receptors. Br J Pharmacol 2010, 160:847–859.View ArticlePubMedPubMed CentralGoogle Scholar
  51. Manthorpe M, Engvall E, Ruoslahti E, Longo F, Davis G, Varon S: Laminin promotes neuritic regeneration from cultured peripheral and central neurons. J Cell Biol 1983, 97:1882–1890.View ArticlePubMedGoogle Scholar
  52. Anton E, Sandrock A, Matthew W: Merosin promotes neurite growth and Schwann cell migration in vitro and nerve regeneration in vivo: evidence using an antibody to merosin. Dev Biol 1994, 164:133–146.View ArticlePubMedGoogle Scholar
  53. Liesi P: Laminin-immunoreactive glia distinguish regenerative adult CNS systems from non-regenerative ones. EMBO J 1985, 4:2505–2511.PubMedPubMed CentralGoogle Scholar
  54. Malinda K, Wysocki A, Koblinski J, Kleinman H, Ponce M: Angiogenic laminin-derived peptides stimulate wound healing. Int J Biochem Cell Biol 2008, 40:2771–2780.View ArticlePubMedPubMed CentralGoogle Scholar
  55. Nguyen B, Ryan M, Gil S, Carter WG: Deposition of laminin 5 in epidermal wounds regulates integrin signaling and adhesion. Curr Opin Cell Biol 2000, 12:554–562.View ArticlePubMedGoogle Scholar
  56. Katoh H, Hosono K, Ito Y, Suzuki T, Ogawa Y, Kubo H, Kamata H, Mishima T, Tamaki H, Sakagami H, Sugimoto Y, Narumiya S, Watanabe M, Majima M: COX-2 and prostaglandin EP3/EP4 signaling regulate the tumor stromal proangiogenic microenvironment via CXCL12-CXCR4 chemokine systems. Am J Pathol 2010, 176:1469–1483.View ArticlePubMedPubMed CentralGoogle Scholar
  57. Urushibata S, Hozumi K, Ishikawa M, Katagiri F, Kikkawa Y, Nomizu M: Identification of biologically active sequences in the laminin alpha2 chain G domain. Arch Biochem Biophys 2010, 497:43–54.View ArticlePubMedGoogle Scholar
  58. Shibuya S, Wakayama Y, Inoue M, Kojima H, Oniki H: Merosin (laminin-2) localization in basal lamina of normal skeletal muscle fibers and changes in plasma membrane of merosin-deficient skeletal muscle fibers. Med Electron Microsc 2003, 36:213–220.View ArticlePubMedGoogle Scholar
  59. Wagner S, Tagaya M, Koziol J, Quaranta V, del Zoppo G: Rapid disruption of astrocyte interaction with the extracellular matrix mediated by integrin alpha6 beta4 during focal cerebral ischemia/reperfusion. Stroke 1997, 28:858–865.View ArticlePubMedGoogle Scholar
  60. Chen Z, Yu H, Yu W, Pawlak R, Strickland S: Proteolytic fragments of laminin promote excitotoxic neurodegeneration by up-regulation of the KA1 subunit of the kainate receptor. J Cell Biol 2008, 183:1299–1313.View ArticlePubMedPubMed CentralGoogle Scholar
  61. Skrzypiec A, Maiya R, Chen Z, Pawlak R, Strickland S: Plasmin-mediated degradation of laminin gamma-1 is critical for ethanol-induced neurodegeneration. Biol Psych 2009, 66:785–794.View ArticleGoogle Scholar
  62. Narumiya S, FitzGerald G: Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest 2001, 108:25–30.View ArticlePubMedPubMed CentralGoogle Scholar
  63. Hata A, Breyer R: Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther 2004, 103:147–166.View ArticlePubMedGoogle Scholar
  64. Harris S, Padilla J, Koumas L, Ray D, Phipps R: Prostaglandins as modulators of immunity. Trends Immunol 2002, 23:144–150.View ArticlePubMedGoogle Scholar
  65. Legler D, Bruckner M, Uetz-von Allmen E, Krause P: Prostaglandin E2 at new glance: novel insights in functional diversity offer therapeutic chances. Int J Biochem Cell Biol 2010, 42:198–201.View ArticlePubMedGoogle Scholar
  66. Tsuji T, Aoshiba K, Yokohori N, Nagai A: A systemically administered EP2 receptor agonist stimulates pulmonary angiogenesis in a murine model of emphysema. Prostaglandins Other Lipid Mediat 2009, 90:85–88.View ArticlePubMedGoogle Scholar
  67. Ueno T, Suzuki T, Oikawa A, Hosono K, Kosaka Y, Amano H: Recruited bone marrow cells expressing the EP3 prostaglandin E receptor subtype enhance angiogenesis during chronic inflammation. Biomed Pharmacother 2010, 64:93–100.View ArticlePubMedGoogle Scholar
  68. Jiang W, Zhang S, Zhu H, Hou J: Effect of 8-O-acetyl Shanzhiside methylester increases angiogenesis and improves functional recovery after stroke. Basic Clin Pharmacol Toxicol 2011, 108:21–27.View ArticlePubMedGoogle Scholar
  69. Seevinck P, Deddens L, Dijkhuizen R: Magnetic resonance imaging of brain angiogenesis after stroke. Angiogenesis 2010, 13:101–111.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© Ji and Tsirka; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement

Journal of Neuroinflammation

ISSN: 1742-2094